Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript

Core Insights - The business has significantly evolved over the past year, particularly in the TAVR segment, with a pivotal event being the presentation of early clinical trial data in late 2024, which addressed durability concerns of the SAPIEN valve family [1] - The early TAVR data, especially regarding asymptomatic patients, has generated considerable momentum for the business in 2025 [1] Group 1 - The 7-year trial data on the durability of SAPIEN valves has been influential, particularly in the PARTNER 3 low-risk study [2]